The prompt increased hepatitis C screening rates among baby boomers in primary care by 5-fold.
HIV, hepatitis B, and hepatitis C infections are more common among individuals with severe mental illness.
The update includes 30 new medicines for adults and 25 for children and groups antibiotics into 3 distinct categories.
Hepatitis C treatment in HIV coinfection cases is effective with standardized nurse and pharmacist support for patients in an urban clinic.
Most opioid-dependent pregnant patients understand that intravenous drug use is a major transmission modality of HCV.
Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and in patients with alcohol-induced cirrhosis.
Patients with chronic HCV infection who have achieved a sustained virologic response with treatment may still be at risk for complications such as hepatocellular carcinoma.
Aggressive testing, diagnosis, treatment, and prevention methods, such as needle exchange for those who inject drugs, are some of the options that the NASEM explored to target hepatitis elimination.
Harvoni and Sovaldi have been approved for pediatric patients with HCV genotypes.
Regimens for the treatment of hepatitis C that included ribavirin had more mild or moderate adverse events than those without.
Drug-drug interactions are common in patients taking hepatitis C virus medications, and consulting with a pharmacist can be beneficial.
HCV infection is associated with cancers such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.
Diabetes could increase the risk of developing hepatocellular carcinoma in patients with hepatitis C.
A VA center in Wisconsin is advising veterans to be screened for hepatitis and HIV after receiving care from a dentist who did not follow VA procedures.
Treatment for 12 or 24 weeks is safe and efficacious for kidney transplant recipients with hepatitis C virus.
Researchers identified an interaction between ribavirin with paritaprevir/ritonavir/ombitasvir and dasabuvir.
The cost of the new hepatitis C drugs in low- and certain middle-income countries is rapidly declining, according to a WHO study.
Patients with HIV receiving antiretroviral treatment have a higher risk of non-Hodgkin's lymphoma with HBV and HCV coinfection.
The FDA issues a warning about the risk of hepatitis B virus reactivation among patients taking direct-acting antivirals to treat hepatitis C infections.
Shortening the duration of HCV therapy from 12 weeks to 3 weeks could substantially reduce the cost of treatment.
In patients with Hepatitis C, Oral treatment with sofosbuvir plus ribavirin is preferred over interferon based triple therapy.
HCVcAg assays with signal amplification have the potential to replace NAT in settings with high HCV prevalence.
A new hepatology rotation increased the mean comfort level for managing several liver diseases.
In a study, 24% of confiscated drug snorting straws tested positive for human blood.
Patients previously treated for HCC have a high risk of tumor recurrence in the long term.
The combination drug treats 6 strains of chronic hepatitis C.
Patients with hepatitis C who had a multidisciplinary team during treatment had improved outcomes.
The number of deaths associated with hepatitis C is higher than the total number of deaths resulting from 60 other infectious diseases.
Direct-acting antivirals pose challenges in patients with hepatitis C and prior hepatocellular carcinoma
Treatment guidelines must expand to focus on patients co-infected with both HCV and HIV.